MedTrace Logo

Evaluating the Safety and Effectiveness of the Tixel Fractional System in the Treatment of Photodamage at Low Settings

NCT05182502 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-04-06

No results posted yet for this study

Summary

To demonstrate the safety and performance of the Tixel fractional system for treatment of photodamage using low-energy settings.

Conditions

  • Wrinkle

Interventions

DEVICE

Tixel

Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage

Sponsors & Collaborators

  • Novoxel Ltd.

    collaborator INDUSTRY

  • Eric Bernstein, MD

    lead OTHER

Principal Investigators

  • Eric F. Bernstein, MD · Main Line Center for Laser Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-07
Primary Completion
2023-09-30
Completion
2023-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182502 on ClinicalTrials.gov